Europe — EMA
Navelbine (Vinorelbine)
GNH USA supplies Navelbine (Vinorelbine), a Vinca alkaloid for non‑small cell lung cancer and metastatic breast cancer. Request a quote for global supply.
Request sourcing
What is Vinorelbine?
Vinorelbine, the active ingredient in Navelbine, is a Vinca alkaloid presented as an oral capsule for oral use. It treats non‑small cell lung cancer and metastatic breast cancer in adult patients.
GNH USA supplies Navelbine as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.
What is Vinorelbine used for?
Vinorelbine is used in oncology to target rapidly dividing tumor cells.
Non‑small cell lung cancer: improves disease control and overall survival in adult patients. Metastatic breast cancer: reduces tumor progression and may extend survival in advanced disease.
What are the side effects of Vinorelbine?
Vinorelbine may cause a range of adverse reactions, from mild to severe.
Common Side Effects: - Nausea and vomiting - Neutropenia (low white‑blood‑cell count) - Constipation - Fatigue - Alopecia (hair loss)
Serious or Rare Side Effects: - Severe neutropenia with febrile infection - Pulmonary toxicity (interstitial pneumonitis) - Peripheral neuropathy - Anaphylactic or severe allergic reactions - Cardiac arrhythmias or conduction disturbances
What precautions apply to Vinorelbine?
Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for toxicity.
Monitor blood counts: perform regular complete blood count assessments. Assess liver function: check hepatic enzymes prior to and during treatment. Evaluate pulmonary status: avoid use in patients with pre‑existing severe lung disease. Avoid strong CYP3A4 inhibitors: these may increase vinorelbine exposure. Use effective contraception: vinorelbine is teratogenic and should not be used during pregnancy. Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.
What does Vinorelbine interact with?
Vinorelbine can interact with several drug classes, requiring careful management.
Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise vinorelbine plasma levels. - Concurrent myelosuppressive agents (e.g., cyclophosphamide): increase risk of severe bone‑marrow suppression.
Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can enhance gastrointestinal toxicity. - Anticoagulants (e.g., warfarin): may require closer INR monitoring.
